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Background: Sepsis and bacterial meningitis are major causes of mortality and morbidity in neonates and
infants. Meropenem, a broad-spectrum antibiotic, is not licensed for use in neonates and infants below 3 months
of age and sufficient information on its plasma and CSF disposition and dosing in neonates and infants is lacking.
Objectives: To determine plasma and CSF pharmacokinetics of meropenem in neonates and young infants and
the link between pharmacokinetics and clinical outcomes in babies with late-onset sepsis (LOS).
Methods: Data were collected in two recently conducted studies, i.e. NeoMero-1 (neonatal LOS) and NeoMero-2
(neonatal meningitis). Optimally timed plasma samples (n"401) from 167 patients and opportunistic CSF sam-
ples (n"78) from 56 patients were analysed.
Results: A one-compartment model with allometric scaling and fixed maturation gave adequate fit to both
plasma and CSF data; the CL and volume (standardized to 70 kg) were 16.7 (95% CI 14.7, 18.9) L/h and 38.6
(95% CI 34.9, 43.4) L, respectively. CSF penetration was low (8%), but rose with increasing CSF protein, with 40%
penetration predicted at a protein concentration of 6 g/L. Increased infusion time improved plasma target
attainment, but lowered CSF concentrations. For 24 patients with culture-proven Gram-negative LOS, pharmaco-
dynamic target attainment was similar regardless of the test-of-cure visit outcome.
Conclusions: Simulations showed that longer infusions increase plasma PTA but decrease CSF PTA. CSF penetra-
tion is worsened with long infusions so increasing dose frequency to achieve therapeutic targets should be
considered.
Introduction
Sepsis and bacterial meningitis are major causes of mortality and
morbidity in neonates and infants and can be considered as part of
a single continuum in that septic infants can develop meningitis.1,2
Late-onset sepsis (LOS) is defined as sepsis starting 72 h or more
after birth.
Meropenem is a broad-spectrum carbapenem antibiotic with
activity against common pathogens causing neonatal sepsis and
meningitis. It is bactericidal against Escherichia coli, Klebsiella spp.,
Enterobacter spp. and Pseudomonas spp.,3 which are known to
cause LOS, and also against pathogens responsible for bacterial
meningitis such as Streptococcus agalactiae (i.e. group B strepto-
cocci), E. coli, Listeria monocytogenes, Haemophilus influenzae,
Streptococcus pneumoniae and Neisseria meningitidis.2,4
Meropenem pharmacodynamics (PD) is usually described by
the percentage of time when concentrations are above the MIC
(%T.MIC). Approximately 40%T.MIC is believed to be sufficient for a
bactericidal effect;5,6 however, for immunocompromised patients,
including neonates, higher targets have been suggested7 and a
recent study looking at meropenem PD indices determined the PD
target for neonates to be 61%T.MIC.
8 For lower respiratory tract
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infections, %T.5% MIC was suggested.9 Meropenem is predomi-
nantly renally eliminated and approximately 75% is excreted
unchanged in the urine.10,11 As a polar, hydrophilic molecule, mer-
openem’s penetration into the CSF through the blood–brain barrier
is limited under normal, healthy conditions, but this may increase
when the meninges are inflamed.12,13
Meropenem is currently unlicensed in infants below 3 months
of age and, whilst there are studies describing its pharmacokinetics
(PK) in neonates and infants,14–18 only Smith et al.15 studied both
plasma and CSF concentrations, including single CSF concentra-
tions from only six patients. Since the concentration–time profile of
meropenem differs between plasma and CSF, taking the ratio of
CSF to plasma is confounded by time after dose. To correctly
assess the fractional CSF penetration necessitates sufficient
sample numbers and timing for a model-based estimation.
Consequently, sufficient information on meropenem’s disposition
to infer dosing in this population is lacking. The NeoMero
Consortium recently completed two studies with PK sampling
from both plasma and CSF: NeoMero-1 [‘Efficacy, pharmacoki-
netics and safety of meropenem in subjects below 90 days of age
(inclusive) with clinical or confirmed late-onset sepsis: a European
multicentre randomised phase III trial’] compared meropenem
with standard of care (b-lactam plus aminoglycoside);19 and
NeoMero-2 [‘Pharmacokinetics and safety of meropenem in sub-
jects below 90 days of age (inclusive) with probable and confirmed
meningitis: a European multicentre phase I-II trial’]. Since some
patients recruited to NeoMero-1 developed meningitis and trans-
ferred to NeoMero-2, the aim of this study was to report a joint
analysis of the plasma and CSF PK results from both studies. We
further sought links with outcome (PD) in NeoMero-1 (LOS) in order
to inform dosing for LOS.
Patients and methods
Ethics
In NeoMero-1, subjects were recruited from 15 centres in six different coun-
tries (Estonia, Greece, Italy, Lithuania, Spain and Turkey). There were,
on average, 8 subjects/centre (range 1–25). In NeoMero-2, there were
21 centres in seven countries (Estonia, Greece, Italy, Lithuania, the
Netherlands, Spain and the UK) recruiting, on average, 2 subjects/centre
(range 1–9). Independent Ethics Committees in each country approved
the studies, which were registered on EudraCT (2011-001515-31 and
2011-001521-25) and clinicaltrials.gov (NCT01551394 and NCT01554124).
Patient recruitment
The inclusion criteria for NeoMero-1 were: diagnosis of sepsis and postnatal
age (PNA) 90 days, and 72 h of life at sepsis onset. Sepsis was defined
as: (i) sepsis confirmed by a positive bacterial culture, accompanied by an
abnormal clinical or laboratory measurement; or (ii) clinical sepsis, i.e. in
case the bacterial culture was negative, clinical and laboratory criteria
defined by either EMA20 or Goldstein21 had to be met, depending on the
postmenstrual age of the infant. An infant could not be included in the trial
if they received systemic antimicrobials more than 24 h prior to randomiza-
tion. The inclusion criteria for NeoMero-2 were: PNA90 days, clinical signs
indicating bacterial meningitis, or pleocytosis, or a positive Gram stain from
the CSF. An infant was not included in the trial if a CSF device was present or
if meningitis was proven to be non-bacterial. In both studies, written
informed consent was required from the parents or legal guardians of the
infant. Exclusion criteria in both studies were: presence of renal failure,
severe congenital malformations, causative pathogen resistant to
meropenem (known or suspected) and known intolerance or contraindica-
tions to meropenem treatment.
Meropenem administration
Meropenem was supplied by Chiesi Pharmaceuticals, Italy. A 12 hourly dose
interval was used in patients with ,32 weeks’ gestational age (GA) and
,2 weeks’ PNA, and 8 hourly in all others. For LOS 20 mg/kg was used and
for meningitis 40 mg/kg was used, these doses and frequencies having
been previously used off-label. Meropenem was infused over 30 min, which
was determined using a now-published model15 (interim version provided
during the protocol development by Professor Caparelli) and simulating the
PTA with different infusion lengths, specifically bolus, 30 min, 1 h and 2 h
infusions. Whilst the 2 h infusion gave a greater PTA, concerns about use of
line space and possible reduced CNS penetration led to a pragmatic deci-
sion to use 30 min infusions.
PK sampling
Plasma sampling for PK was designed to minimize invasiveness whilst max-
imizing information gained. Three optimally timed PK samples were there-
fore decided to be taken from56 subjects, spread evenly over each of the
following age groups:,32 weeks GA and,2 weeks PNA;,32 weeks GA and
2 weeks PNA; 32 weeks GA and ,2 weeks PNA; and 32 weeks GA and
2 weeks PNA. The remaining patients would contribute a single trough
sample. Owing to logistical constraints in that meropenem could be started
at any time, and in an emergency setting, PK sampling was planned to take
place at steady-state. The PK model mentioned in the previous section and
demographics from a previous European neonatal/infant sepsis study22
were used to define optimal sampling times. ED-optimal design (PopED
software23) was used, including interindividual variability. For the three-
sample cohort, optimal times were immediately following the end of the
infusion, 5–6 h post-dose for 8 hourly dosing, 7–8 h post-dose for the young
preterm group dosed 12 hourly and a trough sample immediately before a
dose. For the single sampling optimal design, a trough sample proved most
informative. Since it was not possible to take CSF samples specifically for PK,
these were opportunistically collected when lumbar puncture was per-
formed for other study-specific purposes, with accurate recordings of time,
date and dose history.
Sample handling and meropenem assay
Blood samples were immediately spun down and plasma extracted.
All samples were frozen within 1 h of collection and stored at#80C prior to
analysis. Ultra-HPLC coupled with tandem MS (UHPLC-MS/MS) was used to
determine plasma and CSF meropenem concentrations. To prepare 50lL
of plasma and CSF samples for the analysis, protein precipitation with
methanol and microfiltration (using 0.22lm filters), respectively, were
used. In both cases we used ertapenem as an internal standard. The limit
of detection for the plasma assay was 10 ng/mL and the limit of detection
for the CSF assay was 2 ng/mL. The between-day variability was 4.1%–5%
over the whole calibration range, including the limit of quantification (LoQ)
of 80 ng/mL for the plasma assay; and 3%–5% for the CSF assay with an
LoQ of 6 ng/mL.
PK modelling
PK modelling was undertaken using the first-order conditional estimation
method with interaction (FOCEI) in NONMEM 7.3 (ICON Development
Solutions, Ellicott City, MD, USA).24 Firstly the plasma model was deter-
mined, followed by addition of a compartment for the CSF concentrations.
For the plasma PK, one-, two- and three-compartment structural models
were tested to define the basic structural model. Between-subject variability
was assumed to follow a log-normal distribution, and for the residual error,
proportional, additive, combined and Box–Cox power transformation (with
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both the shape and the scedasticity parameters estimated25) were tested.
To delineate size and age from other possible covariates, body weight
and postmenstrual age were included a priori in the model with allometric
weight scaling and a function describing renal function maturation,
respectively.26 The parameters of the maturation function were fixed
to values from a previous study of human glomerular filtration
development.27 However, since meropenem is renally cleared, and renal
function improves in the days after birth independently of postmenstrual
age, we also tested the effects of PNA and serum creatinine (corrected for
postmenstrual age28) on CL. A covariate was included in the final model, if
(after the inclusion) it produced a drop in the objective function value (OFV)
(DOFV) of .6.63, which corresponds to a P value of ,0.01. The significance
of a covariate was also tested by a randomization test29,30 (n"1000) per-
formed using PsN.31 Since most patients were expected to contribute one
CSF sample, the CSF volume was fixed to 0.15 L/70 kg32 and so two parame-
ters were estimated: the inter-compartmental CL between plasma and CSF,
and the fraction of meropenem penetration from the central compartment
into the CSF. Markers of CNS inflammation (CSF proteins, lactate concentra-
tion, glucose concentration or number of white blood cells per unit of vol-
ume) may correlate with blood–brain barrier function; therefore, the effects
of these covariates on penetration fraction were investigated. When these
covariates were missing, they were replaced with the median.
Basic goodness-of-fit plots [observations versus predictions, conditional
weighted residuals (CWRES) versus time and prediction] in addition to visual
predictive checks with 1000 replicates were used during model-building
and to select the final model. A non-parametric bootstrap analysis was per-
formed (n"1000) on the final model to test parameter robustness and
derive uncertainty around the parameter estimates.
PD analysis of LOS
For NeoMero-1 patients with culture-proven Gram-negative bloodstream
infections for which an MIC could be determined and who received at least
24 h of treatment, the model was used to generate individual AUC0–24:MIC,
Cmax:MIC, Cmin:MIC and %T.MIC. These were compared with whether the
patient successfully completed the treatment course with clinical/labora-
tory improvement (success) or if treatment had to be modified at the dis-
cretion of the treating physician or the patient died (failure). These
endpoints were measured at the test-of-cure visit 2+1 days after the end
of planned therapy (11+3 days). The Kruskal–Wallis test was used to com-
pare the two groups.
Simulations
Monte Carlo simulations (n"1000) using the final model estimates were
used to generate %T.MIC curves for different dosing regimens and the fol-
lowing MIC values: 0.25, 0.5, 1, 2, 4, 8 and 16 mg/L. The unbound fraction of
meropenem was fixed to 0.98.33 The %T.MIC curves were generated using
plasma (for LOS) or CSF (for meningitis) predictions. The PD target was set
to 61%T.MIC;
8 and simulations were done for all four age groups.
Results
Demographics and PK samples
A total of 167 patients underwent PK sampling in the NeoMero
studies, with 123 from NeoMero-1 (5 of whom were diagnosed
with probable or confirmed bacterial meningitis and transferred to
NeoMero-2) and 49 (including the 5 from NeoMero-1) in NeoMero-
2. At enrolment, their median (range) weight was 2.12 (0.48–
6.32) kg, PNA was 13 (1–90) days and gestational age (GA) was
33.3 (22.6–41.9) weeks. Patients from the NeoMero-1 study were
more premature (median GA of 31.9 weeks versus 37.1 weeks in
NeoMero-2) and therefore also weighed less than the patients
from the NeoMero-2 study. Demographics are presented in
Table 1.
Three optimally timed plasma samples were collected from
109 patients, whilst 44 provided a single trough sample. Sampling
numbers from the remaining patients were two (nine patients),
four (four patients) and seven (one patient). There was an even
spread in PNA and GA of optimally timed samples with 25, 18, 20
and 24 patients, respectively, providing three optimal samples in
each of the pre-defined age categories (,32 weeks GA and
,2 weeks PNA; ,32 weeks GA and 2 weeks PNA; 32 weeks GA
and ,2 weeks PNA; and 32 weeks GA and 2 weeks PNA).
Following sample analysis, 11 meropenem peak plasma samples
were below 10 mg/L indicating possible data entry error and were
thus excluded from the analysis to prevent biasing the model
development. The influence of these data points was tested with
the final plasma model and, although the changes in the typical
final model parameter estimates were below 10%, the interindi-
vidual variability and the uncertainty approximately doubled,
again giving a reason for their exclusion. The data set for model-
building therefore contained 401 plasma samples and 78 CSF
samples (CSF was obtained from 56 patients). The median (range)
of CSF sampling time was 5.27 (0–12.0) h post-dose. Plots of the
raw data are presented in Figure 1. One CSF protein concentration
was also excluded from the analysis, as it was not deemed biologi-
cally plausible (102 g/L).
Meropenem clearance is significantly related to
renal function, and CSF penetration to CSF
protein concentration
The final plasma population PK model was a one-compartment
model. Weight was included with allometric scaling (with
exponents fixed to 1 for central volume and 0.632 for CL27) and
postmenstrual age was included with a maturation function
(with parameters fixed to values from a study of renal develop-
ment27). PNA did not significantly improve the model fit;
however, serum creatinine concentration (standardized by
postmenstrual age) proved to have a significant effect on
meropenem clearance (DOFV of 19.7) and was therefore also
included in the final model.
An additional compartment was added to describe merope-
nem CSF PK and to estimate the penetration of meropenem from
plasma to the CSF. Out of the tested covariates, both the CSF lac-
tate concentration and the CSF total protein concentration proved
to significantly explain the CSF penetration (DOFVs of 24.3 and
24.4, respectively). However, since there were fewer missing
measurements for CSF protein concentration (there were 86 pro-
tein and 54 lactate concentrations available, with 58 and 41 of
these, respectively, taken at the time of CSF meropenem sam-
pling), this covariate was included in the final model. The signifi-
cance of the covariates was also confirmed by a randomization
test.29,30
Initially, a proportional model was chosen for the residual error
of both plasma and CSF data; however, Box–Cox power transfor-
mations of the residual error25 resulted in an improved fit (DOFV of
67.8) and there was an improvement in the distribution of the
residuals; therefore, this residual error model was used.
The estimate for the scedasticity parameter corresponding to the
CSF concentrations was approximately zero and there was no
Meropenem plasma and CSF PK in neonates JAC
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improvement whether it was estimated or not; therefore, it was
fixed to zero. The final model parameters are presented in Table 2.
The diagnostic plots showed adequate fit to the data (i.e. agree-
ment between the measured and predicted concentrations
was observed and there was no particular trend in the residual
plots) (Figure 2) and the visual predictive check (using 1000 repli-
cates) confirmed that the model had good simulation properties
(Figure 3).
In vitro PD target reached in all culture-proven cases
In the NeoMero-1 study there were 24 individuals with culture-
proven LOS with a Gram-negative organism for which MIC values
were available and at least 24 h of meropenem had been adminis-
tered. Of these, 12 patients were considered to have been success-
fully treated (no need to modify the treatment course), whereas
12 patients failed (2 died, 9 required treatment modification at the
discretion of the treating physician and 1 still had unresolved
symptoms). The mean MIC in the 12 successes was 0.27 mg/L,
whereas in the 12 failures the mean MIC was 0.98 mg/L (P"0.38).
All patients had a %T.MIC above 61% (the proposed in vitro-derived
target8); there was no difference in AUC0–24:MIC ratio (P"0.53) or
in Cmin:MIC ratio (P"0.73) in patients classified as treatment fail-
ures versus successes (Figure 4). Simulations of %T.MIC showed lit-
tle difference between bolus and 30 min infusions (data not
shown) and so a comparison of 20 and 40 mg/kg bolus versus con-
tinuous infusion are shown in Figure 5 (with a frequency of 8 hourly
or 12 hourly for those ,32 weeks gestation and ,2 weeks PNA as
per our study dosing).
Discussion
This population PK model describing plasma and CSF disposition of
meropenem in infants aged ,90 days with LOS and/or bacterial
meningitis represents the largest study of meropenem PK in
infants aged 90 days to have been reported to date, which also
included the highest number of collected CSF samples in this popu-
lation. The generally accepted target of 40%T.MIC is believed to be
adequate for bactericidal effects of carbapenems,5 but a recent
in vitro study has suggested that differences in the PK profile in
neonatal patients means a higher target of 61%T.MIC is war-
ranted.8 All of our patients with culture-proven Gram-negative LOS
achieved this target, but it should be noted that most MIC values
were 0.25 mg/L. Simulations showed that 90% of patients
should achieve 61%T.MIC for organisms with an MIC of 2 mg/L
and so our major finding is that, for meropenem-susceptible
organisms, a 20 mg/kg bolus appears to be a sufficient dose for
LOS (Figure 5).
A recent randomized controlled trial of continuous versus
30 min meropenem infusion in neonates with culture-proven
infection found decreased mortality and ventilator support
required in the continuous infusion group.34 Whilst no MICs were
recorded in this study, which also found surprisingly high failure of
microbial eradication at 7 days (30% overall), it is not the only clini-
cal study to report improved outcomes with differing meropenem
Cmin. High %T.MIC has also been reported to be associated with
improved clinical outcomes in adult lower respiratory tract infec-
tion,9 with a breakpoint of Cmin of 5 times the MIC being associated
with maximum benefit.
The simulations in Figure 5 show that the same dose given as a
continuous infusion achieves higher Cmin:MIC ratios. Simulations
Table 1. Demographics of included subjects
All data NeoMero-1 NeoMero-2
Number of subjectsa 167 123 49
Weight (kg), median (range) 2.12 (0.48–6.32) 1.68 (0.48–5.01) 3.11 (0.60–6.32)
GA (weeks), median (range) 33.3 (22.6–41.9) 31.9 (22.6–41.3) 37.1 (23.4–41.9)
PNA (days), median (range) 13 (1–90) 15 (3–83) 9 (1–90)
Postmenstrual age (weeks), median (range) 37.4 (23.7–51.3) 36.0 (23.7–51.3) 38.8 (24.9–51.1)
Female, n (%) 78 (46.7) 59 (48.4) 19 (42.2)
Number of plasma samples 401 255 147
Plasma samples per patient, mean 2.4 2.1 3.0
Number of CSF samples 78 32 46
CSF samples per patient, mean 0.47 0.26 0.94
Plasma concentration (mg/L), median (range) 7.94 (0.01–147.7) 5.27 (0.01–147.7) 12.4 (0.1–139.0)
CSF concentration (mg/L), median (range) 1.58 (0.04–35.4) 1.23 (0.04–7.34) 1.90 (0.05–35.4)
Plasma time after the dose (h), median (range) 5.66 (0–12.4) 5.93 (0–12.4) 5.19 (0–12.2)
CSF time after the dose (h), median (range) 5.27 (0–12.0) 5.99 (0–12.0) 5.03 (0–11.5)
Creatinine (lmol/L), median (range) 32.0 (3.54–197.4) 34.5 (3.54–197.4) 27.0 (6.0–133)
C-reactive protein (mg/L), median (range) 23.0 (0.3–280) 23.2 (0.3–242) 22.4 (0.4–280)
Procalcitonin (ng/mL), median (range) 2.7 (0.1–377.2) 2.8 (0.1–128.6) 1.8 (0.1–377.2)
For creatinine, C-reactive protein and procalcitonin, the summary statistics represent all samples recorded during the study.
Day 0" first day of life.
Weight, PNA and GA–at enrolment.
aFive infants switched from NeoMero-1 to NeoMero-2.
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from our model based on a breakpoint of 2 mg/L showed that
standard 20 mg/kg dosing would achieve the in vitro-derived tar-
get of 61%T.MIC
8 in 90% of patients, but if the MIC were to increase
to 4 mg/L as organisms become intermediately resistant, it would
be necessary to increase dosing to 40 mg/kg. The use of a continu-
ous infusion with an 8 hourly dose of 40 mg/kg (i.e. 120 mg/kg in
24 h) would be required to achieve a Cmin:MIC ratio of .5 for an
MIC of around 1 mg/L and continuous infusions do clearly increase
plasma %T.MIC (Figure 5). Simply moving to continuous infusions
may, however, not be appropriate, particularly in this clinical set-
ting where patients with LOS can go on to develop meningitis. As
can be seen in Figure 5, continuous infusions give substantially
lower CNS concentrations for the same total daily dose. This is
likely due to low Cmax resulting in lower peripheral concentrations.
The association between longer meropenem infusions and lower
Cmax has also been previously shown.
14
The data in our study have substantially increased the literature
on meropenem CSF PK, which enables simulated dosing schemes
to balance circulating and CSF concentrations. The only study that
focused on meropenem plasma and CSF disposition in infants
(,3 months of age) to date involved six patients, who provided
nine CSF samples.15 Smith et al.15 reported that uptake of merope-
nem into the CSF was 70%, determined by comparing plasma and
CSF concentrations at the same timepoint. This method is subopti-
mal since the CSF and plasma time courses vary as b-lactams
enter the CSF through paracellular pathways,35 resulting in a
delayed peak CSF concentration. Our model-based typical esti-
mate for the fraction of meropenem penetration from plasma into
the CSF was 8.4%, which is at the lower end of the values previ-
ously reported in the literature: 10% up to 30%35,36 or 40%37 and
this could be because the meninges were not inflamed13 in many
of the NeoMero-1 patients without meningitis; median CSF protein
and CSF lactate concentrations were almost in normal ranges
(1.2 g/L and 1.8 mmol/L, respectively). We did find a significant
increase in CNS penetration with increasing CSF protein concentra-
tion, with penetration reaching over 40% when CSF protein con-
centration exceeded 6 g/L. Overall the CNS penetration results
show that the fraction entering the CNS is low and comparable
with other populations, although when inflammation is present, as
evidenced by the presence of proteins in the CSF, penetration sig-
nificantly increases.
The values of the PK parameters for a typical infant from
this study (weight"2.1 kg, postmenstrual age"37.4 weeks,
serum creatinine"32lmol/L, CSF protein concentration"1.2
mmol/L and serum creatinine, standardized by postmenstrual
age"60lmol/L) were: CL"0.39 L/h and V"1.17 L. These values
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Figure 1. Plot of meropenem concentration versus time after dose for plasma and CSF. The top two plots show data for NeoMero-1 and the bottom
two plots show data for NeoMero-2. Data points from the same individual are joined with a broken line (these are not always taken from the same
dosing interval).
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Table 2. Population PK model final parameter estimates
Mean SE %CV g-shrinkage (%) Bootstrap, median (95% CI)
CL (L/h/70 kg) 16.7 1.07 — — 16.7 (14.7, 18.9)
h_creatinine #0.40 0.094 — — #0.40 (#0.58,#0.21)
V (L/70 kg) 38.6 2.15 — — 38.6 (34.9, 43.4)
CLCSF (L/h/70 kg) 0.017 0.004 — — 0.016 (0.001, 0.030)
CSF uptakea 2.39 0.205 — — 2.38 (2.01, 2.82)
h_CSF proteinsa #0.17 0.110 — — #0.17 (#0.43, 0.015)
IIV on CL 0.255 0.058 50.5 13.5 0.248 (0.154, 0.370)
IIV on V 0.153 0.059 39.1 31.0 0.154 (0.042, 0.282)
Cov IIV CL-V 0.167 0.055 — — 0.163 (0.070, 0.277)
RUV_plasma 0.679 0.108 — — 0.664 (0.489, 0.900)
RUV_CSF 1.19 0.125 — — 1.15 (0.941, 1.391)
Lambda_plasma 0.280 0.107 — — 0.275 (0.064, 0.482)
Lambda_CSF 0.285 0.107 — — 0.279 (0.066, 0.485)
Delta_plasma #0.174 0.052 — — #0.178 (#0.287,#0.063)
SE, standard error from NONMEM covariance step; CV, coefficient of variation; IIV, between-subject variability; Cov, covariance; RUV, residual error; h,
estimated covariate effect.
Lambda and delta are parameters from the dynamic-transform-both-side approach for residual error modelling (more specifically, lambda is the
shape parameter and delta is the scedasticity parameter; together they are a part of the Box–Cox power parameter, zeta" lambda!delta).
aIndicates that the value is on the logit scale.
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Figure 2. Basic goodness-of-fit plots for the final model. The top two plots show observed concentration (DV) versus population predictions (PRED)
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are in agreement with what has been previously reported in the lit-
erature. For example, van den Anker et al.16 found that CL was
0.43 L/h and V was 0.97 L for a population of premature and
mature infants. When only premature infants with an approxi-
mate weight of 1 kg were studied, the CL was lower, specifically
0.06 L/h14 and 0.15 L/h.17 A lower clearance of 0.13 L/h was also
reported by Smith et al.;15 however, in all these cases the infants
weighed around 1 kg, which would explain the lower CL estimate.
This also is the reason for a 12-hourly frequency to be retained in
the youngest premature age group.
Since meropenem showed low potential for nephrotoxicity,10,38
higher doses do not necessarily mean increased toxicity.35
Therefore, if needed, the doses could be increased or meropenem
could be given more frequently.
Conclusions
A PK model describing plasma and CSF meropenem data in young
infants with confirmed or suspected LOS and/or meningitis was
developed using data from one of the largest infant sepsis trials to
have been conducted in this population. Dosing of 20 mg/kg as an
8 hourly bolus may be adequate for LOS at current MIC targets, but
in future 40 mg/kg may be necessary owing to increasing patho-
gen MICs. Increasing infusion times (up to continuous infusion)
improves circulating %T.MIC, but decreases CSF %T.MIC.
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